Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 2
2001 3
2002 4
2003 4
2004 10
2005 11
2006 17
2007 20
2008 34
2009 32
2010 32
2011 33
2012 43
2013 27
2014 26
2015 44
2016 22
2017 25
2018 27
2019 37
2020 23
2021 16
2022 11
2023 14
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

461 results

Results by year

Filters applied: . Clear all
Page 1
LRP1 and APOA1 Polymorphisms: Impact on Warfarin International Normalized Ratio-Related Phenotypes.
Li D, Luo ZY, Chen Y, Zhu H, Song GB, Zhou XM, Yan H, Zhou HH, Zhang W, Li X. Li D, et al. J Cardiovasc Pharmacol. 2020 Jul;76(1):71-76. doi: 10.1097/FJC.0000000000000834. J Cardiovasc Pharmacol. 2020. PMID: 32282500
Warfarin international normalized ratio (INR)-related phenotypes such as the percentage of INR time in the therapeutic range (PTTR) and INR variability are associated with warfarin adverse reactions. ...In conclusion, the study revealed that the …
Warfarin international normalized ratio (INR)-related phenotypes such as the percentage of INR time in the thera …
Warfarin Therapy and VKORC1 and CYP Genotype.
Dean L. Dean L. 2012 Mar 8 [updated 2018 Jun 11]. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012–. 2012 Mar 8 [updated 2018 Jun 11]. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012–. PMID: 28520347 Free Books & Documents. Review.
Warfarin (brand name Coumadin) is an anticoagulant (blood thinner). ...Therefore, the dose of warfarin must be tailored for each patient according to the patient's response, measured as INR (International Normalized Ratio), and the condit …
Warfarin (brand name Coumadin) is an anticoagulant (blood thinner). ...Therefore, the dose of warfarin must be tailored …
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.
Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, Lee MT, Gage BF, Kimmel SE, Perera MA, Anderson JL, Pirmohamed M, Klein TE, Limdi NA, Cavallari LH, Wadelius M. Johnson JA, et al. Clin Pharmacol Ther. 2017 Sep;102(3):397-404. doi: 10.1002/cpt.668. Epub 2017 Apr 4. Clin Pharmacol Ther. 2017. PMID: 28198005 Free PMC article.
This document is an update to the 2011 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin dosing. Evidence from the published literature is presented for CYP2C9, VKORC1, CYP4F2, and rs12777823 genotyp …
This document is an update to the 2011 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotyp …
Association between apolipoprotein E genotype and warfarin response during initial anticoagulation.
He S, Zhang H, Cao Y, Nian F, Chen H, Chen W, Auchoybur ML, Yin L, Tao Z, Tang S, Chen X. He S, et al. Biomed Pharmacother. 2018 May;101:251-256. doi: 10.1016/j.biopha.2018.02.095. Epub 2018 Feb 27. Biomed Pharmacother. 2018. PMID: 29494962
Whether APOE genotypes mediate the warfarin response is unknown. The aim of this study was to evaluate the genetic contributions of different APOE genotypes to the early phase of anticoagulation in Han Chinese patients. We conducted a retrospective coh …
Whether APOE genotypes mediate the warfarin response is unknown. The aim of this study was to evaluate the genetic contributio …
Genotype-guided dosing of warfarin through modeling and simulation.
Deng J, Vozmediano V, Rodriguez M, Cavallari LH, Schmidt S. Deng J, et al. Eur J Pharm Sci. 2017 Nov 15;109S:S9-S14. doi: 10.1016/j.ejps.2017.05.017. Epub 2017 May 11. Eur J Pharm Sci. 2017. PMID: 28502675 Review.
Current genotype-guided algorithms for warfarin dosing fail to deliver optimal performance in two aspects: 1) these algorithms are not able to achieve the same level of benefits in non-white populations, since they were developed based on multivariate regression ana …
Current genotype-guided algorithms for warfarin dosing fail to deliver optimal performance in two aspects: 1) these algorithms …
Relationship between warfarin dosage and international normalized ratio: a dose-response analysis and evaluation based on multicenter data.
Xue L, Zhang Y, Xie C, Zhou L, Liu L, Zhang H, Xu L, Song H, Lin M, Qiu H, Zhu J, Zhu Y, Zou J, Zhuang W, Xuan B, Chen Y, Fan Y, Wu D, Shen Z, Miao L. Xue L, et al. Eur J Clin Pharmacol. 2019 Jun;75(6):785-794. doi: 10.1007/s00228-019-02655-8. Epub 2019 Apr 29. Eur J Clin Pharmacol. 2019. PMID: 31037455
PURPOSE: The objectives of the study were to establish a dose-response model for warfarin based on the relationship between daily warfarin dose and international normalized ratio (INR) and to evaluate the stability and reliability of the establi …
PURPOSE: The objectives of the study were to establish a dose-response model for warfarin based on the relationship between daily …
International normalized ratio stabilization in newly initiated warfarin patients with nonvalvular atrial fibrillation.
Nelson WW, Desai S, Damaraju CV, Lu L, Fields LE, Wildgoose P, Schein JR. Nelson WW, et al. Curr Med Res Opin. 2014 Dec;30(12):2437-42. doi: 10.1185/03007995.2014.957822. Epub 2014 Sep 2. Curr Med Res Opin. 2014. PMID: 25170587
BACKGROUND: Warfarin is effective for stroke prevention in patients with atrial fibrillation (AF), but international normalized ratio (INR) levels fluctuate and frequent monitoring is necessary. METHODS: This study used data from a large anticoagula …
BACKGROUND: Warfarin is effective for stroke prevention in patients with atrial fibrillation (AF), but international normal …
Theory-based pharmacokinetics and pharmacodynamics of S- and R-warfarin and effects on international normalized ratio: influence of body size, composition and genotype in cardiac surgery patients.
Xue L, Holford N, Ding XL, Shen ZY, Huang CR, Zhang H, Zhang JJ, Guo ZN, Xie C, Zhou L, Chen ZY, Liu LS, Miao LY. Xue L, et al. Br J Clin Pharmacol. 2017 Apr;83(4):823-835. doi: 10.1111/bcp.13157. Epub 2016 Nov 25. Br J Clin Pharmacol. 2017. PMID: 27763679 Free PMC article.
Genotypes were measured using pyrosequencing. A sequential population PK parameter with data method was used to describe the international normalized ratio (INR) time course. ...Patients with VKORC1 AA and CYP4F2 CC or CT genotypes had lower C50 …
Genotypes were measured using pyrosequencing. A sequential population PK parameter with data method was used to describe the inter …
Kinetic-pharmacodynamic model of warfarin for prothrombin time-international normalized ratio in Japanese patients.
Hirai T, Aoyama T, Tsuji Y, Itoh T, Matsumoto Y, Iwamoto T. Hirai T, et al. Br J Clin Pharmacol. 2024 Mar;90(3):828-836. doi: 10.1111/bcp.15967. Epub 2023 Dec 10. Br J Clin Pharmacol. 2024. PMID: 37953511
AIMS: Genotype-guided dosing algorithms can explain about half of the interindividual variability in prothrombin time-international normalized ratio (PT-INR) under warfarin treatment. This study aimed to refine a published kinetic-pharmacodynami …
AIMS: Genotype-guided dosing algorithms can explain about half of the interindividual variability in prothrombin time-internationa …
Variations in prothrombin time-international normalized ratio caused by drug-drug interaction in patients receiving warfarin: A retrospective observational study.
Shiraishi C, Hirai T, Fujita S, Dohi K, Iwamoto T. Shiraishi C, et al. Int J Clin Pharmacol Ther. 2023 Apr;61(4):139-147. doi: 10.5414/CP204306. Int J Clin Pharmacol Ther. 2023. PMID: 36633369
Few studies have clarified the clinical impact of CYP2C9 inhibitors and inducers on warfarin therapy. Here, we evaluated the clinical impact of CYP2C9-mediated interactions on the pharmacodynamics of warfarin. MATERIALS AND METHODS: This retrospective observational …
Few studies have clarified the clinical impact of CYP2C9 inhibitors and inducers on warfarin therapy. Here, we evaluated the clinical …
461 results